Published in Lab Business Week, September 23rd, 2007
Current medical therapies for the treatment of atrial fibrillation have substantial clinical limitations. Sodium channel blockers are contraindicated in patients with coronary artery or structural heart disease, potassium channel blockers can predispose patients to dangerous ventricular arrhythmias and mixed ion channel blockers such as amiodarone can be associated with multi-organ toxicity as well as ventricular arrhythmias.
There is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week